Eli Lilly lowered its earnings and revenue outlook for the full year 2019 due to the costs relating to the pending purchase of Loxo Oncology and the recent trial failure of cancer-treating Lartruvo.
In the fourth quarter, revenue rose 5% driven by increased demand for newer medicines as well as an 11% increase in volume. Revenue in the US increased 7% driven by increased volume, backed by newer pharmaceutical products, including Trulicity, Taltz, and Basaglar.
The company reported revenues increases across all its products such as lung cancer treating chemotherapy Alimta, type 2 diabetes medication Trulicity, autoimmune diseases treating injectable drug Taltz, solid tumors treating drug Cyramza, high blood sugar controlling insulin Basaglar, type 2 diabetes medication Jardiance, and chemotherapy Lartruvo, primarily driven by increased demand.
Take a look at results in a graphical format at https://news.alphastreet.com/eli-lilly-q4-2018-earnings-lly-stock/
In the fourth quarter, revenue rose 5% driven by increased demand for newer medicines as well as an 11% increase in volume. Revenue in the US increased 7% driven by increased volume, backed by newer pharmaceutical products, including Trulicity, Taltz, and Basaglar.
The company reported revenues increases across all its products such as lung cancer treating chemotherapy Alimta, type 2 diabetes medication Trulicity, autoimmune diseases treating injectable drug Taltz, solid tumors treating drug Cyramza, high blood sugar controlling insulin Basaglar, type 2 diabetes medication Jardiance, and chemotherapy Lartruvo, primarily driven by increased demand.
Take a look at results in a graphical format at https://news.alphastreet.com/eli-lilly-q4-2018-earnings-lly-stock/